Windtree Therapeutics Stock Alpha and Beta Analysis
| WINT Stock | USD 0.61 0.05 8.89% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Windtree Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Windtree Therapeutics over a specified time horizon. Remember, high Windtree Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Windtree Therapeutics' market risk premium analysis include:
Beta 4.13 | Alpha (3.90) | Risk 12.64 | Sharpe Ratio (0.25) | Expected Return (3.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Windtree |
Windtree Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Windtree Therapeutics market risk premium is the additional return an investor will receive from holding Windtree Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Windtree Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Windtree Therapeutics' performance over market.| α | -3.9 | β | 4.13 |
Windtree Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Windtree Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Windtree Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Windtree Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Windtree Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Windtree Therapeutics shares will generate the highest return on investment. By understating and applying Windtree Therapeutics stock market price indicators, traders can identify Windtree Therapeutics position entry and exit signals to maximize returns.
Windtree Therapeutics Return and Market Media
The median price of Windtree Therapeutics for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 0.92 with a coefficient of variation of 112.85. The daily time series for the period is distributed with a sample standard deviation of 2.41, arithmetic mean of 2.13, and mean deviation of 1.69. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Windtree Therapeutics Expands Stock and Restructures Finances - TipRanks | 09/13/2024 |
2 | Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock | 09/25/2024 |
3 | Windtree Therapeutics Announces Positive Phase 2b Results For Istaroxime In Early Cardiogenic Shock Treatment | 10/07/2024 |
4 | Acquisition by Craig Fraser of 5431 shares of Windtree Therapeutics at 0.9099 subject to Rule 16b-3 | 10/08/2024 |
5 | WINT Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones | 10/14/2024 |
6 | Disposition of 249004 shares by Bioengine Capital Inc. of Windtree Therapeutics at 12.15 subject to Rule 16b-3 | 10/18/2024 |
7 | Short Interest in Windtree Therapeutics, Inc. Grows By 301.8 | 11/12/2024 |
8 | ARMISTICE CAPITAL, LLC Acquires New Stake in Windtree Therapeutics Inc | 11/15/2024 |
9 | WINT Water Intelligence and Polygon enter partnership to deliver enhanced water damage prevention | 11/21/2024 |
About Windtree Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Windtree or other stocks. Alpha measures the amount that position in Windtree Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Interest Debt Per Share | 69.47 | 65.99 | Revenue Per Share | 22.77 | 21.63 |
Windtree Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Windtree Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Windtree Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Windtree Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Windtree Therapeutics. Please utilize our Beneish M Score to check the likelihood of Windtree Therapeutics' management manipulating its earnings.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Windtree Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.